Kolon Life Science secures TG-C patent in Canada "Boost for commercialization"

[Financial News] Kolon Life Science announced on the 11th that a patent related to the 'method for evaluating the efficacy of cell therapy products' for the cell gene therapy 'TG-C' (formerly Invossa) being developed by its affiliate Kolon TissueGene has been decided for registration in Canada.
This patent was jointly filed by Kolon Life Science and Kolon TissueGene, and has been registered in 7 countries including the USA, Japan, China, Australia, Hong Kong, and Singapore, now including Canada. The company explained that this strengthens the technical reliability and market monopoly base necessary for the global commercialization of TG-C.
TG-C is a cell gene therapy that injects a mixture of △allogeneic cartilage-derived chondrocytes (liquid 1) and △transformed cells introduced with the 'TGF-β1' gene (liquid 2) into the knee joint cavity at a ratio of 3:1. It helps to suppress inflammation, alleviate pain, and improve joint function and structure.
The core of this patent is that it has established a standard for quantitatively evaluating the efficacy and quality of TG-C. By using the expression levels of TGF-β1 secreted from liquid 2 and 'TSP-1' produced from liquid 1 as efficacy indicators, it can be confirmed that the therapeutic effect is uniformly maintained when expressed above a certain level.
TSP-1 is a multifunctional protein important for maintaining immune homeostasis.
Kolon Life Science expects that this objective evaluation standard will act as a key driver in the process of global expansion.
Cell therapy products are based on living cells, making them sensitive to changes in the production environment, and ensuring quality consistency is considered a key challenge for commercialization. Regulatory authorities and global partners place great importance on whether standards can be secured to prove the scientific efficacy and quality reproducibility of the therapy.
The strategic significance of the Canadian market is also great. Canada is a technologically advanced country with strict regulatory standards and a rapidly growing market in the field of cell therapy products. The Canadian cell therapy market is expected to grow at an average annual rate of 24.29% from 2023 to 2033, reaching approximately 1.0605 billion dollars (about 1.5 trillion won) by 2033.
Kim Sun-jin, CEO of Kolon Life Science, said, "The registration of the Canadian patent has strengthened the foundation for objectively evaluating the osteoarthritis treatment effect of TG-C," adding, "This is an important achievement that enhances scientific credibility for global market entry."


vrdw88@fnnews.com Kang Jung-mo Reporter